$599
Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i

FDA Warns Against Glucose-Sensing Smartwatches; Novo Nordisk Foundation Invests in CVRM Diagnosis and Prevention; AZ Initiates Dapa/Zibotentan Ph2b Study; Tandem Initiates an Extended Infusion Set Study

Four cardiometabolic-related news items have been observed from FDA, the Novo Nordisk Foundation, AstraZeneca, and Tandem Diabetes Care. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home